A survey of primary care physicians in five Swedish regions recorded 190 responses in October 2024 [1]. Separate research on barriers to getting a GLP-1 prescription considers what can prevent patients from starting. This survey asked physicians what made prescribing difficult at the time.
What the physicians reported
The final sample of 163 respondents excludes incomplete or ineligible replies. Ninety-eight percent agreed that GLP-1 drugs were effective for treating obesity, and 91% expected them to be important in future care [1]. Low availability was cited by 86%, and high patient copayments by 69%. These percentages describe the surveyed physicians’ responses. They do not show how often patients were denied prescriptions.
What the results can tell patients today
The survey response rate was 28%. Since GLP-1 insurance coverage in the United States depends on the plan and indication, the Swedish cost figures do not predict a US copayment. The availability finding describes October 2024, when the authors reported supply shortages. Physicians who chose to respond may have differed from those who did not.